Cancer Genetics — Q1 2015 Earnings Presentation
12 slides from Cancer Genetics's earnings presentation, May 12, 2015
Slide 1: Q1 2015 Earnings Call
May 12, 2015 Q1 2015 Earnings Call
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potenti
Slide 3: 1st Quarter 2015 Revenue Highlights
1st Quarter 2015 Revenue Highlights 3 Cancer Genetics, Inc. | NASDAQ: CGIX | Q1 2015 Earnings Call Q 1 2 0 1 2 Q 1 2 0 1 3 Q 1 2 0 1 4 Q 1 2 0 1 5 0 $4.4 $1.4 $1.2 $0.8 4-Year CAGR 53% $4.5M $2M 578% BIOPHARMA REVENUE GROWTH FROM Q1 2014 Q1 TOTAL REVENUE GREW FROM $1.4M TO 206% REVENUE GROWTH FROM Q
Slide 4: Revenues By Category
Revenues By Category 4 Cancer Genetics, Inc. | NASDAQ: CGIX | Q1 2015 Earnings Call 76% 20% 4% Q1 2015 BIOPHARMA SERVICES CLINICAL SERVICES DISCOVERY SERVICES $10.2 Mn $4.4 Mn Launched new NGS panels, including Focus::Myeloid™ Repositioning of Go-To Market Strategy to concentration on clinical s
Slide 5: Q1 2015 Financial Highlights
Q1 2015 Financial Highlights 5 First quarter 2015 revenues were $4.4 million, a 206% increase over first quarter 2014 revenues of $1.4 million, and 8+% sequential growth over $4.0 million in the fourth quarter of 2014 Revenue from Biopharma Services grew 578% year-over-year during the first quar
Slide 6: Summary Statement of Operations
Summary Statement of Operations 6 Income Statement Item ($ in Thousands) Q1 2013 Q1 2014 Q1 2015 Revenue $1,219 $1,430 $4,370 Gross Profit 149 140 1,229 Gross Margin (%) 12% 10% 28% Research & Development (R&D) 491 597 1,278 Sales & Marketing (S&M) 397 749 1,116 General & Administrative (G&A) 1,571
Slide 7: Expected Future Biopharma Revenues
Expected Future Biopharma Revenues 7 Approximate expected future revenues under signed contracts with biotechnology and pharma customers for testing and services to support currently planned clinical trials. Cancer Genetics, Inc. | NASDAQ: CGIX | Q1 2015 Earnings Call December 2013 December 2012 Dec
Slide 8: Significant Progress in our Disease-Specific NGS Panel Pipeline
Significant Progress in our Disease-Specific NGS Panel Pipeline 8 Cancer Genetics, Inc. | NASDAQ: CGIX | Q1 2015 Earnings Call RESEARCH & DISCOVERY CLINICAL DEVELOPMENT COMMERCIAL DEVELOPMENT LAUNCH & MARKET ENTRY FOCUS::CLL™ FOCUS::MYELOID™ (IN COLLABORATION WITH ILLUMINA) FOCUS::LYMPHOID™ MULTIPLE
Slide 9: Focus::CLL NGS Panel
Focus::CLL™ NGS Panel 9 Cancer Genetics, Inc. | NASDAQ: CGIX | Q1 2015 Earnings Call Launched in Q4 2014 Unique targeted NGS panel with 7 biomarkers for diagnosis, prognosis and patient management The only targeted NGS panel available for CLL/SLL Selected for use in global clinical trial by
Slide 10: Focus::Myeloid NGS Panel
Focus::Myeloid™ NGS Panel 10 Cancer Genetics, Inc. | NASDAQ: CGIX | Q1 2015 Earnings Call Launched in Q1 2015 Comprehensive NGS panel with 54 biomarkers that provides actionable information for improved diagnosis, prognosis, and risk stratification Delivers faster results on biomarkers in curr
Slide 11: Upcoming Milestones
Upcoming Milestones 11 Increasing covered lives market access through additional payers & health care organizations Additional international agreements for FHACT® distribution and co-marketing partnerships in key geographies Launching multi-marker NGS panel for lymphoid malignancies Multiple
Slide 12: Thank You
Thank You Cancer Genetics, Inc. www.cancergenetics.com CGI Headquarters Meadows Office Complex 201 Route 17 North, 2nd Floor Rutherford, NJ 07070 Phone: +1 201-528-9200 Fax: +1 201-528-9235 Research Triangle Park 133 Southcenter Court, Ste. 400 Morrisville, NC 27569 Phone: +1 919-465-0100 Fax: +1 91